# US 2023/0405100 A1 · Vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0405100 A1
- Document ID: US20230405100A1
- Status: Published application
- Kind: A1
- Application number: 18/166,420
- Filed: 2023-02-08
- Published: 2023-12-21
- Earliest claimed: 2017-03-03
- Assignees: Treos Bio Limited
- Applicants: Treos Bio Limited
- Inventors: Julianna Lisziewicz; Levente Molnár; Eniko R. Toke; József Toth; Orsolya Lorincz; Zsolt Csiszovszki; Eszter Somogyi; Katalin Pántya; Mónika Megyesi
- Web page: https://patentgrep.com/patent/US20230405100A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001184: {Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 35/00: Antineoplastic agents
- C12Q 1/6869: Methods for sequencing
- G01N 33/505: {involving T-cells}
- G01N 33/56977: {HLA or MHC typing}
- G01N 33/575: for cancer
- G16B 15/30: Drug targeting using structural data; Docking or binding prediction
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- A61K 39/0002: {Fungal antigens, e.g. Trichophyton, Aspergillus, Candida}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55544: {Bacterial toxins}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55594: {from bacteria}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2039/605: {MHC molecules or ligands thereof}
- A61K 2039/6075: {Viral proteins}
- A61K 2039/70: {Multivalent vaccine}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The disclosure relates to polypeptides and pharmaceutical compositions comprising polypeptides that find use in the prevention or treatment of cancer, in particular breast cancer, ovarian cancer and colorectal cancer. The disclosure also relates to methods of inducing a cytotoxic T cell response in a subject or treating cancer by administering pharmaceutical compositions comprising the peptides, and companion diagnostic methods of identifying subjects for treatment. The peptides comprise T cell epitopes that are immunogenic in a high percentage of patients.

## Claims

### Claim at position 1

-22. (canceled)

### Claim 23

A pharmaceutical composition, comprising: (i) a peptide having an amino acid sequence comprising that of any of SEQ ID NOs: 332-346; and (ii) a pharmaceutically acceptable adjuvant.

### Claim 24

A pharmaceutical composition, comprising: (i) at least a first peptide and a second peptide, each peptide having a different amino acid sequence comprising that of any of SEQ ID NOs: 302-331; and (ii) a pharmaceutically acceptable adjuvant.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, further comprising at least one additional peptide, wherein the at least one additional peptide has an amino acid sequence that is: (i) a different sequence from the first and the second peptides of claim 24; and (ii) comprises that of any of SEQ ID NOs: 272-301.

### Claim 26 (depends on 23)

The pharmaceutical composition of claim 23, further comprising at least one additional peptide comprising a fragment of an antigen selected from OY-TES-1, PIWIL-2, PIWIL-3, PIWIL-4, BORIS, AKAP4, WT1, HIWI, EpCam, SP17, SPAG9, PRAME, and SURVIVIN.

### Claim 27 (depends on 23)

The pharmaceutical composition of claim 23, wherein the peptide is encoded by a nucleic acid molecule.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, wherein the nucleic acid molecule is selected from DNA and RNA.

### Claim 29 (depends on 27)

The pharmaceutical composition of claim 27, wherein the nucleic acid molecule is RNA.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, wherein the RNA: (i) is selected from non-replicating mRNA or virally-derived, self-amplifying RNA; and/or (ii) comprises a non-naturally occurring nucleotide or a modified nucleoside.

### Claim 31 (depends on 23)

A method of treating ovarian cancer, comprising administering the pharmaceutical composition of claim 23 to an individual in need thereof.

### Claim 32

A pharmaceutical composition, comprising: (i) at least a first peptide and a second peptide, each peptide having a different amino acid sequence comprising that of any of SEQ ID NOs: 41-60, 64, or 195-233; and (ii) a pharmaceutically acceptable adjuvant.

### Claim 33 (depends on 32)

The pharmaceutical composition of claim 32, wherein the combination of the first peptide and the second peptide has an amino acid sequence comprising that of any of SEQ ID NOs: 81-111 or 435-449.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, further comprising at least one additional peptide, wherein the at least one additional peptide has an amino acid sequence that is: (i) a different sequence from the first and the second peptides of claim 33; and (ii) comprises that of any of SEQ ID NOs: 1-20, or 175-194.

### Claim 35 (depends on 32)

The pharmaceutical composition of claim 32, further comprising at least one additional peptide comprising a fragment of an antigen selected from TSGA10, PIWIL-2, AKAP4, PLU-1, RHOXF-2, SPAG9, EpCam, HIWI, ODF-4, NY-SAR-35, RHOXF-2, PRAIVIE, MAGE-A9, MAGE-A11, SP17, BORIS, Survivin, HOM-TES-95, NY-BR-1, and NY-ESO-1.

### Claim 36 (depends on 32)

The pharmaceutical composition of claim 32, further comprising at least one additional peptide comprising a fragment of an antigen selected from AKAP4, BORIS, SPAG9, NY-SAR-35, PRAME, SURVIVIN, MAGE-A9, MAGE-A11, NY-BR-1, and HomTes85.

### Claim 37 (depends on 32)

The pharmaceutical composition of claim 32, wherein the peptide is encoded by a nucleic acid molecule.

### Claim 38 (depends on 37)

The pharmaceutical composition of claim 37, wherein the nucleic acid molecule is selected from DNA and RNA.

### Claim 39 (depends on 37)

The pharmaceutical composition of claim 37, wherein the nucleic acid molecule is RNA.

### Claim 40 (depends on 39)

The pharmaceutical composition of claim 39, wherein the RNA: (i) is selected from non-replicating mRNA or virally-derived, self-amplifying RNA; and/or (ii) comprises a non-naturally occurring nucleotide or a modified nucleoside.

### Claim 41 (depends on 32)

A method of treating breast cancer, comprising administering the pharmaceutical composition of claim 32 to an individual in need thereof.
